COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #215 of 237
12/16 Late treatment study
Signes-Costa et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012 (Peer Reviewed)
Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases
Source   PDF   Share   Tweet
47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung disease in Canada, China, Cuba, Ecuador, Germany, Italy and Spain, 83% treated with HCQ/CQ.
Multivariable Cox regression HCQ/CQ mortality hazard ratio HR 0.53, p < 0.001.

Signes-Costa et al., 12/16/2020, retrospective, Spain, Canada, China, Cuba, Ecuador, Germany, Italy, Europe, Asia, Caribbean, North America, South America, peer-reviewed, 28 authors.
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 4854, control 993, adjusted per study.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit